Form 424B3 Nobilis Health Corp.
Table of Contents
Filed Pursuant to Rule 424(b)(3)
Registration No. 333-224584
NOBILIS HEALTH CORP.
2,608,087 Common Shares
This prospectus relates to the resale of up to 2,608,087 common shares, no par value (the “Shares”), of Nobilis Health Corp. (the “Company”) by the selling securityholders, representing (i) 378,788 outstanding Shares, and (ii) up to 2,229,299 Shares issuable upon conversion of a $3.5 million convertible promissory note issued by the Company (the “Convertible Note”). The Convertible Note and the Shares were issued in connection with the Company’s acquisition of a 50.1% ownership interest in four privately-held entities in November 2017.
The selling securityholders may offer and sell the Shares from time to time in amounts, at prices and on terms that will be determined at the time of the offering, which may be determined by prevailing market prices or in negotiated transactions. See “Plan of Distribution” beginning on page 7. We will not receive any of the proceeds from the resale of the Shares by the selling securityholders. However, the issuance of the Shares upon conversion of the Convertible Note would be in satisfaction of our obligation for the principal amount payable thereunder.
You should carefully read this prospectus and any accompanying prospectus supplement, together with the documents we incorporate by reference, before you invest in the Shares.
Our common shares are presently quoted on the NYSE American under the symbol “HLTH” and on the Aequitas NEO Exchange under the symbol “HLTH”. On May 8, 2018, the last sale price of our common shares as reported on the NYSE American was $1.35 per share.
Investing in our common shares involves substantial risk. Please read “Risk Factors” beginning on page 4 of this prospectus and any risk factors described in any applicable prospectus supplement and in the documents we incorporate by reference.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
Prospectus dated May 9, 2018
Table of Contents
| Page | ||||
| 1 | ||||
| 2 | ||||
| 4 | ||||
| 4 | ||||
| 5 | ||||
| 6 | ||||
| 7 | ||||
| 8 | ||||
| 8 | ||||
| 8 | ||||
| 8 | ||||
i
Table of Contents
Unless otherwise indicated or the context otherwise requires, references in this prospectus to the “Company,” “Nobilis,” “we,” “us” and “our” refer to Nobilis Health Corp. and its subsidiaries.
This prospectus is part of registration statements that we filed with the Securities and Exchange Commission (the “Commission”). Under the registration process, the selling securityholders may, from time to time, offer and sell the Shares described in this prospectus in one or more offerings. This prospectus provides you with a general description of the Shares that the selling securityholders may offer. Each time the selling securityholders sell securities under this registration statement, we may provide a prospectus supplement that will contain additional information about the terms of that offering. The prospectus supplement may also add, update or change information contained in this prospectus. Any statement that we make in this prospectus will be modified or superseded by any inconsistent statement made by us in a prospectus supplement.
You should read this prospectus and any applicable prospectus supplement, together with the information incorporated herein by reference as described under the heading “Information Incorporated by Reference.”
You should rely only on the information that we have provided or incorporated by reference in this prospectus and any applicable prospectus supplement. We have not authorized any dealer, salesman or other person to give any information or to make any representation other than those contained or incorporated by reference in this prospectus or any applicable prospectus supplement. You should not rely upon any information or representation not contained or incorporated by reference in this prospectus or the accompanying prospectus supplement. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you.
This prospectus and any accompanying prospectus supplement do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the registered securities to which they relate, nor do this prospectus and any accompanying prospectus supplement constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction. You should not assume that the information contained in this prospectus or any applicable prospectus supplement is accurate on any date subsequent to the date set forth on the front of the document or that any information we have incorporated by reference is correct on any date subsequent to the date of the document incorporated by reference, even though this prospectus or any applicable prospectus supplement is delivered or securities are sold on a later date.
1
Table of Contents
This summary highlights certain information appearing elsewhere in this prospectus and in the documents we incorporate by reference into this prospectus. The summary is not complete and does not contain all of the information that you should consider before investing in our common shares. After you read this summary, you should read and consider carefully the entire prospectus and any prospectus supplement and the more detailed information and financial statements and related notes that are incorporated by reference into this prospectus and any prospectus supplement. If you invest in our common shares, you are assuming a high degree of risk.
Our Company
Nobilis Health Corp. (“Nobilis” or the “Company”) was incorporated on March 16, 2007 under the name “Northstar Healthcare Inc.” pursuant to the provisions of the British Columbia Business Corporations Act. On December 5, 2014, Northstar Healthcare Inc. changed its name to Nobilis Health Corp. Prior to December 1, 2014, our business was solely the ownership, operation and management of outpatient surgery centers and specialty surgical hospitals (the “Medical Segment”). On December 1, 2014, we completed the acquisition of Athas Health, LLC. This acquisition added marketing services as a stand-alone business line, which is now a separate reportable business segment (the “Marketing Segment”). In addition to providing services to third parties, our unique direct-to-patient marketing and proprietary technology serves our own healthcare facilities.
Our portfolio of specialty surgical hospitals, ambulatory surgical centers (ASCs), and multi-specialty clinics is complemented by our Marketing Segment, which allows us to operate those facilities in many instances with few, if any, physician partners. Our differentiated business strategy provides value to patients, physicians and payors, and enables us to capitalize on recent trends in the healthcare industry, particularly with regard to increased consumerism in the healthcare space. As a result, we believe we are positioned for continued growth.
As of December 31, 2017, there are 33 locations across Texas and Arizona, including specialty surgical hospitals, ASCs and multi-specialty clinics. Additionally, Nobilis partnered with another 34 facilities across the country, and marketed 9 independent brands. We provide care across a variety of specialties in our facilities including, pain management, spine surgery, orthopedic surgery, bariatric surgery, plastic surgery, ear nose and throat (ENT), podiatric surgery, vein and vascular, and other general surgery.
Many of our surgical patients require additional complementary healthcare services and Nobilis has spent the last two years developing a full suite of ancillary services that we offer patients treated in our facilities. To date, Nobilis is able to provide a variety of in-house ancillary services, such as Anesthesia, Surgical Assist, and Intraoperative Neuromonitoring. The addition of the ancillary services has helped us successfully expand our continuum of care, increase facility efficiency, improve our coordination of the various services they require, enhance the quality of our patients’ clinical outcomes as well as their overall experience.
On October 28, 2016 and March 8, 2017, we purchased Arizona Vein and Vascular Center, LLC and its four affiliated surgery centers operating as Arizona Center for Minimally Invasive Surgery, LLC and Hamilton Vein Center brand and associated assets, respectively. These acquisitions expanded our specialty mix to include the treatment of venous diseases with little modification to our existing infrastructure of specialty surgical hospitals and ASCs. Our facilities will be able to offer a range of treatments, both surgical and non-surgical, for those patients suffering from venous diseases, which today affect more than 30 million Americans.
In addition to our vein and vascular business acquisitions, on September 13, 2017, we purchased DeRosa Medical, P.C. (“DeRosa”). DeRosa is a primary care practice that specializes in health and wellness, medically supervised weight loss, women’s health, and chronic health condition management. The practice operates three multi-specialty clinics within the Phoenix, Arizona metropolitan area, specifically in Scottsdale, Chandler, and Glendale. The acquisition of DeRosa allows the Company to expand its continuum of care by providing additional healthcare services at the primary care level.
On November 15, 2017, the Company purchased 50.1% ownership interests in Elite Sinus Spine and Ortho LLC, Elite Center for Minimally Invasive Surgery, LLC, Houston Metro Ortho and Spine Surgery Center, LLC and Elite Hospital Management, LLC (collectively the “Management Companies” or collectively, “Elite”) that manage three ASCs and one specialty surgical hospital in Houston, TX. Elite provides healthcare management services to these facilities, which generate 100% in-network revenue to the Nobilis system. This acquisition represents a strategic opportunity to enhance Nobilis’ in-network revenue and adds 76 physician partners to our existing network of surgeons in the Houston market. We will also have the opportunity to leverage best practices from both companies, generate operational efficiencies, further improve our case conversion through a substantial increase in referral-based business and provide the Company additional resources to strengthen Nobilis’ footprint within the Houston market.
2
Table of Contents
On November 15, 2017, Northstar Healthcare Surgery Center – Houston, LLC, a subsidiary of the Company (“Northstar”), acquired a 50.1% ownership interest in Houston Metro Ortho and Spine Surgery Center LLC, a Texas limited liability company, Elite Hospital Management LLC, a Texas limited liability company, Elite Center for Minimally Invasive Surgery LLC, a Texas limited liability company, and Elite Sinus Spine and Ortho LLC, a Texas limited liability company (collectively, “Elite”) that manage three ASCs and one specialty surgical hospital in Houston, Texas (the “Transaction”). Elite provides healthcare management services to these facilities, which generate 100% in-network revenue to the Nobilis system. This acquisition represents a strategic opportunity to enhance Nobilis’ in-network revenue and adds 76 physician partners to our existing network of surgeons in the Houston market. We will also have the opportunity to leverage best practices from both companies, generate operational efficiencies, further improve our case conversion through a substantial increase in referral-based business and provide the Company additional resources to strengthen Nobilis’ footprint within the Houston market.
Our principal executive offices are located at 11700 Katy Freeway, Suite 300, Houston, Texas. Our telephone number is (713) 355-8614. Our website address is www.nobilishealth.com. Information on our website is not part of this prospectus.
The Offering
This prospectus relates to the resale of up to 2,608,087 Shares of the Company by the selling securityholders, representing (i) 378,788 outstanding Shares, and (ii) up to 2,229,299 Shares issuable upon conversion of the Convertible Note.
Such Shares and the Convertible Note were issued pursuant to the Transaction. At the closing, the Company and Northstar paid the sellers approximately $60.1 million, comprised of $53.6 million in cash, $3.5 million in the form of the Convertible Note, $2.5 million in the form of an unfunded escrow and 378,788 Shares to an agent of the sellers.
The Convertible Note bears interest at 6.75% per annum and is payable in three installments over a two year period. The Convertible Note (outstanding principal plus any accrued but unpaid interest, collection and enforcements costs, and any other amounts or charges incurred under thereunder) may be converted into Shares upon the occurrence of both (i) default, and (ii) the election of the note holder. The number of Shares issued will equal to the quotient obtained by dividing the conversion amount by the lessor of (i) the closing bid price of the Shares on the trading day immediately prior to the conversion date, or (ii) the volume weighted average price of the common shares on NYSE American in the trailing ten trading days prior to the maturity date. In addition, if, within three business days of the transmittal of the notice of conversion to the Company, the Shares have a closing bid price that is 5% or lower than the conversion price set forth in the notice of conversion, the conversion price shall be the average closing bid price of the Shares during such three-business day period. We have estimated the number of Shares issuable upon conversion of the Company’s Convertible Note based upon the $3.5 million principal amount and a conversion price equal to the volume-weighted average price over the seven trading days ending April 25, 2018, which equals $1.57.
| Securities Offered | ||
| Shares outstanding prior to this offering |
78,183,802 Shares. | |
| Shares to be offered by the selling securityholders |
2,608,087 Shares, consisting of 378,788 outstanding Shares and up to 2,229,299 Shares issuable upon conversion of the Convertible Note held by the selling securityholder. | |
| Shares outstanding after this offering |
80,413,101 Shares, which includes up to 2,229,299 Shares that may be issued upon conversion of the Convertible Note held by the selling securityholder. | |
| Use of Proceeds |
We will not receive any of the proceeds from the sale by the selling securityholders of Shares in this offering. All proceeds from the sale of the Shares will be paid directly to the selling securityholders. | |
| NYSE American symbol |
“HLTH” | |
3
Table of Contents
Investing in our common shares involves a high degree of risk. You should carefully consider and evaluate the risk factors included in our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q that we file with the Commission, which are incorporated herein by reference, together with the risk factors and other information contained in or incorporated by reference into any prospectus supplement, before making an investment decision. The occurrence of any of these risks and uncertainties could harm our business, financial condition, results of operations or growth prospects. As a result, the trading price of our common shares could decline, and you could lose all or part of your investment.
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
Information set forth in this prospectus and any prospectus supplement and the information it incorporates by reference contain certain forward-looking statements within the meaning of Canadian and United States securities laws, including the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts and may be identified by the use of words including, but not limited to the following: “may,” “believe,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “continue” or the negative thereof or other variations thereon or comparable terminology, or by discussions of strategy. These forward-looking statements are based on the Company’s current plans and expectations and are subject to a number of risks, uncertainties and other factors that could significantly affect current plans and expectations and our future financial condition and results. These factors, which could cause actual results, performance and achievements to differ materially from those anticipated, include, but are not limited to the following:
| • | our ability to successfully maintain effective internal controls over financial reporting; |
| • | our ability to implement our business strategy, manage the growth in our business, and integrate acquired businesses; |
| • | the risk of litigation and investigations, and liability claims for damages and other expenses not covered by insurance; |
| • | the risk that payments from third-party payers, including government healthcare programs, may decrease or not increase as costs increase; |
| • | adverse developments affecting the medical practices of our physician limited partners; |
| • | our ability to maintain favorable relations with our physician limited partners; |
| • | our ability to grow revenues by increasing case and procedure volume while maintaining profitability; |
| • | failure to timely or accurately bill for services; |
| • | our ability to compete for physician partners, patients and strategic relationships; |
| • | the risk of changes in patient volume and patient mix; |
| • | the risk that laws and regulations that regulate payments for medical services made by government healthcare programs could cause our revenues to decrease; |
| • | the risk that contracts are cancelled or not renewed or that we are not able to enter into additional contracts under terms that are acceptable to us; and |
| • | the risk of potential decreases in our reimbursement rates. |
Other factors include the risk factors set forth elsewhere in this prospectus under the heading “Risk Factors” beginning on page 4 of this prospectus, in any applicable prospectus supplement and in our Annual Report on Form 10-K for the fiscal year ended December 31, 2017, filed on March 12, 2018, as updated by other filings with the Commission.
This prospectus, any prospectus supplement and the information incorporated herein and therein by reference should be read completely and with the understanding that actual future results may be materially different from what we may expect. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of the
4
Table of Contents
document in which they are made or, if a date is specified, as of such date, when evaluating the information presented in this prospectus or other disclosures because current plans, anticipated actions, and future financial conditions and results may differ from those expressed in any forward-looking statements made by or on behalf of the Company.
Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
This prospectus relates to Shares that may be offered and sold from time to time by the selling securityholders. We will not receive any of the proceeds resulting from the sale of Shares by the selling securityholders. The selling securityholders will receive all of the proceeds from this offering. However, the issuance of the Shares upon conversion of the Convertible Note would be in satisfaction of our obligation for the principal amount payable thereunder.
5
Table of Contents
This prospectus includes the resale of up to 2,608,087 Shares of the Company by the selling securityholders, representing (i) 378,788 outstanding Shares, and (ii) up to 2,229,299 Shares issuable upon conversion of the Convertible Note.
The following table sets forth, based on information provided to us by the selling securityholders or known to us, the names of the selling securityholders, the nature of any position, office or other material relationship, if any, which the selling securityholder has had, within the past three years, with us or with any of our predecessors or affiliates, and the number of Shares beneficially owned by the selling securityholders before this offering. The number of Shares owned are those beneficially owned, as determined under the rules of the Commission, and the information is not necessarily indicative of beneficial ownership for any other purpose. Under these rules, beneficial ownership includes any common shares as to which a person has sole or shared voting power or investment power and any common shares which the person has the right to acquire within 60 days through the exercise of any option, warrant or right, through conversion of any security or pursuant to the automatic termination of a power of attorney or revocation of a trust, discretionary account or similar arrangement. Except as set forth below, none of the selling securityholders is a broker-dealer or an affiliate of a broker-dealer. As of May 1, 2018, there were 78,183,802 common shares issued and outstanding.
We have assumed all Shares reflected on the table will be sold from time to time in the offering covered by this prospectus. Because the selling securityholders may offer all or any portions of the Shares listed in the table below, no estimate can be given as to the actual amount of Shares covered by this prospectus that will be held by the selling securityholders upon the termination of the offering.
| Name of Selling Securityholder |
Number of Shares Beneficially Owned Before Offering |
Number of Shares Offered |
Number of Shares Owned After Offering |
Percentage of Shares Beneficially Owned After Offering |
||||||||||||
| Elite Ambulatory Surgery Centers, LLC (1) |
0 | 2,229,299 | (2) | 0 | (2) | 0 | ||||||||||
| PC Advisors LLC (3) |
378,788 | 378,788 | 0 | 0 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total |
378,788 | 2,608,087 | 0 | 0 | ||||||||||||
| (1) | The address for Elite Ambulatory Surgery Centers, LLC, a Texas limited liability company doing business as Elite Surgical Affiliates, is 2100 West Loop South, Suite 1200, Houston, Texas 77027. |
| (2) | Represents the estimated number of Shares issuable upon conversion of the Convertible Note, calculated based on the principal amount outstanding of $3.5 million and assuming that the conversion price is equal to the volume-weighted average price over the seven trading days ending on April 25, 2018, which was $1.57. |
| (3) | The address for PC Advisors LLC is 8222 Douglas Ave Suite 200, Dallas, Texas 75225. |
6
Table of Contents
The selling securityholders, which as used herein includes donees, pledgees, transferees or other successors-in-interest selling Shares or interests in Shares received after the date of this prospectus from a selling securityholder as a gift, pledge, partnership distribution or other transfer, may, from time to time, sell, transfer or otherwise dispose of any or all of their Shares or interests in Shares on any stock exchange, market or trading facility on which the Shares are traded or in private transactions. These dispositions may be at fixed prices, at prevailing market prices at the time of sale, at prices related to the prevailing market price, at varying prices determined at the time of sale, or at negotiated prices.
The selling securityholders may use any one or more of the following methods when disposing of Shares or interests therein:
| • | ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers; |
| • | block trades in which the broker-dealer will attempt to sell the Shares as agent, but may position and resell a portion of the block as principal to facilitate the transaction; |
| • | purchases by a broker-dealer as principal and resale by the broker-dealer for its account; |
| • | an exchange distribution in accordance with the rules of the applicable exchange; |
| • | privately negotiated transactions; |
| • | short sales effected after the date the registration statement of which this prospectus is a part is declared effective by the Commission; |
| • | through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise; |
| • | a combination of any such methods of sale; and |
| • | any other method permitted by applicable law. |
The selling securityholders may, from time to time, pledge or grant a security interest in some or all of the Shares owned by them and, if they default in the performance of their secured obligations, the pledgees or secured parties may offer and sell the Shares, from time to time, under this prospectus, or under an amendment to this prospectus under Rule 424(b)(3) or other applicable provision of the Securities Act of 1933, as amended (“Securities Act”), amending the list of selling securityholders to include the pledgee, transferee or other successors in interest as selling securityholders under this prospectus. The selling securityholders also may transfer or Shares in other circumstances, in which case the transferees, pledgees or other successors in interest will be the selling beneficial owners for purposes of this prospectus.
In connection with the sale of our Shares or interests therein, the selling securityholders may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the Shares in the course of hedging the positions they assume. The selling securityholders may also sell the Shares short and deliver these Shares to close out their short positions, or loan or pledge the Shares to broker-dealers that in turn may sell these Shares. The selling securityholders may also enter into option or other transactions with broker-dealers or other financial institutions or the creation of one or more derivative securities which require the delivery to such broker-dealer or other financial institution of the Shares offered by this prospectus, which Shares such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).
The selling securityholders also may resell all or a portion of the Shares in open market transactions in reliance upon Rule 144 under the Securities Act, provided that they meet the criteria and conform to the requirements of that Rule.
The selling securityholders and any underwriters, broker-dealers or agents that participate in the sale of the Shares or interests therein may be “underwriters” within the meaning of Section 2(11) of the Securities Act. Any discounts, commissions, concessions or profit they earn on any resale of the Shares may be underwriting discounts and commissions under the Securities Act. Selling securityholders who are “underwriters” within the meaning of Section 2(11) of the Securities Act will be subject to the prospectus delivery requirements of the Securities Act.
7
Table of Contents
To the extent required, the Shares to be sold, the names of the selling securityholders, the respective purchase prices and public offering prices, the names of any agent, dealer or underwriter, or any applicable commissions or discounts with respect to a particular offer will be set forth in an accompanying prospectus supplement or, if appropriate, a post-effective amendment to the registration statement that includes this prospectus.
In order to comply with the securities laws of some states, if applicable, the Shares may be sold in these jurisdictions only through registered or licensed brokers or dealers.
The selling securityholders and any other person participating in such distribution will be subject to applicable provisions of the Securities Exchange Act of 1934, as amended (“Exchange Act”), and the rules and regulations thereunder, including, without limitation, to the extent applicable, Regulation M of the Exchange Act, which may limit the timing of purchases and sales of any of the Shares by the selling security holders and any other participating person. To the extent applicable, Regulation M may also restrict the ability of any person engaged in the distribution of the Shares to engage in market-making activities with respect to the Shares. All of the foregoing may affect the marketability of the Shares and the ability of any person or entity to engage in market-making activities with respect to the Shares.
The selling securityholders may agree to indemnify any agent, dealer, or broker-dealer that participates in transactions involving sales of the Shares if liabilities are imposed on that person by the Securities Act.
We will bear all expenses of the registration of the Shares covered by this prospectus.
We have agreed to keep this registration statement of which this prospectus is a part effective for a period equal to the term of the Note, which has a maturity date of November 15, 2019.
The validity of the Shares offered hereby and certain other legal matters will be passed upon for us by the law firm of Macdonald Tuskey.
The financial statements incorporated in this Prospectus by reference to the Annual Report on Form 10-K for the year ended December 31, 2017 have been incorporated in reliance on the report of Crowe Horwath LLP, an independent registered accounting firm, given on the authority of said firm as experts in accounting and auditing.
WHERE YOU CAN FIND MORE INFORMATION
We file annual, quarterly and special reports, along with other information with the Commission (“SEC Filings”). Our SEC Filings are available to the public over the Internet at the Commission’s website at http://www.sec.gov. You may also read and copy any document we file at the Commission’s Public Reference Room at 100 F Street, NE, Washington, D.C. 20549. Please call the Commission at 1-800-SEC-0330 for further information on the Public Reference Room.
This prospectus and any applicable prospectus supplement is part of a registration statement on Form S-3 that we filed with the Commission to register the securities offered hereby under the Securities Act. This prospectus does not contain all of the information included in the registration statement, including certain exhibits and schedules. You may obtain the registration statement and exhibits to the registration statement from the Commission at the address listed above or from the Commission’s internet site.
INCORPORATION OF DOCUMENTS BY REFERENCE
The Commission allows us to “incorporate by reference” information into this prospectus. This means that we can disclose important information to you by referring you to another document filed separately with the Commission. The information that we incorporate by reference is considered to be part of this prospectus. Because we are incorporating by reference our future filings with the Commission, this prospectus is continually updated and those future filings may modify or supersede some or all of the information included or incorporated in this prospectus. This means that you must look at all of the SEC Filings that we incorporate by reference to determine if any of the statements in this prospectus or in any document previously incorporated by reference have been modified or superseded. This prospectus incorporates by reference the
8
Table of Contents
documents listed below and any future filings we will make with the Commission under Sections 13(a), 14 or 15(d) of the Exchange Act, (i) after the date of the initial registration statement and prior to effectiveness of the registration statement, and (ii) after the date of this prospectus, until the selling securityholders sell all of our securities registered under this prospectus:
| • | Our Annual Report on Form 10-K for the year ended December 31, 2017, filed with the Commission on March 12, 2018, and our Current Reports on Form 8-K filed with the Commission on January 25, 2018, January 29, 2018, January 30, 2018 and March 20, 2018; |
| • | the description of our registered securities contained in our Current Report on Form 8-A filed with the Commission on April 14, 2015 (File No. 001-37349), including any amendment or report filed for the purpose of updating such description; and |
| • | all reports and other documents subsequently filed by us pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act after the date of this prospectus and prior to the termination of this offering. |
Notwithstanding the foregoing, information furnished under Items 2.02 and 7.01 of any Current Report on Form 8-K, including the related exhibits, is not incorporated by reference in this prospectus.
The information about us contained in this prospectus should be read together with the information in the documents incorporated by reference. You may request a copy of any or all of these filings, at no cost, by writing or telephoning us at: Nobilis Health Corp., 11700 Katy Freeway, Suite 300, Houston, Texas, telephone number (713) 355-8614.
9